JP2021529531A - 抗体送達のための組成物及び方法 - Google Patents

抗体送達のための組成物及び方法 Download PDF

Info

Publication number
JP2021529531A
JP2021529531A JP2020573299A JP2020573299A JP2021529531A JP 2021529531 A JP2021529531 A JP 2021529531A JP 2020573299 A JP2020573299 A JP 2020573299A JP 2020573299 A JP2020573299 A JP 2020573299A JP 2021529531 A JP2021529531 A JP 2021529531A
Authority
JP
Japan
Prior art keywords
antibody
seq
recombinant
genome
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020573299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021529531A5 (https=
Inventor
トレバー パリー
プージャ アガーワル
スマ クリシュナン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Krystal Biotech Inc
Original Assignee
Krystal Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krystal Biotech Inc filed Critical Krystal Biotech Inc
Publication of JP2021529531A publication Critical patent/JP2021529531A/ja
Publication of JP2021529531A5 publication Critical patent/JP2021529531A5/ja
Priority to JP2024055149A priority Critical patent/JP7749055B2/ja
Priority to JP2025156650A priority patent/JP2025186440A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—DNA viruses
    • C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
    • C07K16/087—Herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16661—Methods of inactivation or attenuation
    • C12N2710/16662—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2020573299A 2018-06-29 2019-06-28 抗体送達のための組成物及び方法 Pending JP2021529531A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2024055149A JP7749055B2 (ja) 2018-06-29 2024-03-29 抗体送達のための組成物及び方法
JP2025156650A JP2025186440A (ja) 2018-06-29 2025-09-22 抗体送達のための組成物及び方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862692514P 2018-06-29 2018-06-29
US62/692,514 2018-06-29
US201862713066P 2018-08-01 2018-08-01
US62/713,066 2018-08-01
PCT/US2019/039939 WO2020006486A1 (en) 2018-06-29 2019-06-28 Compositions and methods for antibody delivery

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024055149A Division JP7749055B2 (ja) 2018-06-29 2024-03-29 抗体送達のための組成物及び方法

Publications (2)

Publication Number Publication Date
JP2021529531A true JP2021529531A (ja) 2021-11-04
JP2021529531A5 JP2021529531A5 (https=) 2022-06-30

Family

ID=68985203

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020573299A Pending JP2021529531A (ja) 2018-06-29 2019-06-28 抗体送達のための組成物及び方法
JP2024055149A Active JP7749055B2 (ja) 2018-06-29 2024-03-29 抗体送達のための組成物及び方法
JP2025156650A Pending JP2025186440A (ja) 2018-06-29 2025-09-22 抗体送達のための組成物及び方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2024055149A Active JP7749055B2 (ja) 2018-06-29 2024-03-29 抗体送達のための組成物及び方法
JP2025156650A Pending JP2025186440A (ja) 2018-06-29 2025-09-22 抗体送達のための組成物及び方法

Country Status (6)

Country Link
US (1) US20210261649A1 (https=)
EP (1) EP3866924A4 (https=)
JP (3) JP2021529531A (https=)
AU (1) AU2019292580B2 (https=)
CA (1) CA3103374A1 (https=)
WO (1) WO2020006486A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3199552T3 (da) 2012-11-20 2020-03-30 Sanofi Sa Anti-ceacam5-antistoffer og anvendelser heraf
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
RS60410B1 (sr) 2016-04-08 2020-07-31 Krystal Biotech Inc Kompozicije za upotrebu u metodama za tretman rana, poremećaja i bolesti kože
EP3758737A4 (en) 2018-03-02 2022-10-12 Kodiak Sciences Inc. IL-6 ANTIBODIES AND FUSION CONSTRUCTS AND CONJUGATES THEREOF
US10786438B2 (en) 2018-04-27 2020-09-29 Krystal Biotech, Inc. Recombinant nucleic acids encoding cosmetic protein(s) for aesthetic applications
EP3921334A1 (en) 2019-02-08 2021-12-15 Krystal Biotech, Inc. Compositions and methods for delivering cftr polypeptides
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
JP2023547026A (ja) * 2020-09-10 2023-11-09 バスキュラー バイオジェニックス リミテッド 運動精子ドメイン含有タンパク質２抗体およびその使用法
US20220267450A1 (en) 2020-10-14 2022-08-25 Viridian Therapeutics, Inc. Compositions and methods for treatment of thyroid eye disease
AU2021379882A1 (en) 2020-11-10 2023-06-29 Sanofi Ceacam5 antibody-drug conjugate formulation
IL303350A (en) 2020-12-04 2023-08-01 Macrogenics Inc Pharmaceutical compositions of a her2/neu antibody and use of the same
BR112023020209A2 (pt) 2021-04-02 2023-12-19 Krystal Biotech Inc Genoma do vírus do herpes recombinante, vírus do herpes, composição farmacêutica, uso do vírus do herpes ou da composição farmacêutica, método para expressar, realçar, aumentar, ampliar e/ou suplementar os níveis de um polipeptídeo imunomodulatório, método para prover alívio profilático, paliativo ou terapêutico, e, método para tratar câncer
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
TW202330598A (zh) * 2021-06-30 2023-08-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｂａｆｆ和ｉｌ－１２／２３的抗原結合分子及用途
EP4384219A4 (en) 2021-08-10 2025-06-18 Viridian Therapeutics, Inc. COMPOSITIONS, DOSAGES AND METHODS FOR THE TREATMENT OF THYROID EYE DISEASE
EP4413046A4 (en) * 2021-10-05 2025-11-26 Univ Texas PROCESSES AND COMPOSITIONS COMPRISING B7-H3 BONDING POLYPEPTIDES
WO2023083381A1 (zh) 2021-11-15 2023-05-19 成都百利多特生物药业有限责任公司 双特异性抗体-喜树碱类药物偶联物及其医药用途
WO2023224980A1 (en) * 2022-05-17 2023-11-23 The Uab Research Foundation Methods and compositions for treating or preventing inflammatory skin disorders
EP4540284A2 (en) 2022-06-17 2025-04-23 Apogee Therapeutics, Inc. Antibodies that bind interleukin 13 and methods of use
CN119816595A (zh) * 2022-06-30 2025-04-11 隆萨销售股份有限公司 可编辑细胞系
WO2024182737A1 (en) * 2023-03-01 2024-09-06 The Brigham And Women’S Hospital, Inc. Oncolytic viruses to treat brain cancer
CN116790615B (zh) * 2023-07-11 2024-11-22 康霖生物科技（杭州）有限公司 一种用于过敏性疾病的基因治疗载体核酸构建体及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017103291A1 (en) * 2015-12-17 2017-06-22 Psioxus Therapeutics Limited Virus encoding an anti-tcr-complex antibody or fragment
WO2017118866A1 (en) * 2016-01-08 2017-07-13 Replimune Limited Engineered virus

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610287B1 (en) * 1990-04-16 2003-08-26 The General Hospital Corporation Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication
US5658724A (en) * 1992-07-31 1997-08-19 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use
US6261552B1 (en) * 1997-05-22 2001-07-17 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus vectors
GB0203285D0 (en) * 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
PL3718564T3 (pl) * 2003-12-23 2024-03-18 Genentech, Inc. Nowe przeciwciała anty-IL 13 i ich zastosowania
KR20080073293A (ko) * 2005-10-14 2008-08-08 메디뮨 엘엘씨 항체 라이브러리의 세포 디스플레이
NZ580378A (en) * 2007-03-30 2012-11-30 Abbott Lab Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
NO2700405T3 (https=) * 2008-05-29 2018-09-01
WO2016183312A1 (en) * 2015-05-13 2016-11-17 Sanofi Pasteur Biologics, Llc Icp0-mediated enhanced expression system
RS60410B1 (sr) * 2016-04-08 2020-07-31 Krystal Biotech Inc Kompozicije za upotrebu u metodama za tretman rana, poremećaja i bolesti kože

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017103291A1 (en) * 2015-12-17 2017-06-22 Psioxus Therapeutics Limited Virus encoding an anti-tcr-complex antibody or fragment
WO2017118866A1 (en) * 2016-01-08 2017-07-13 Replimune Limited Engineered virus

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CURRENT OPINION IN VIROLOGY, vol. 21, JPN6023021142, 2016, pages 93 - 101, ISSN: 0005208441 *
STEM CELLS, vol. 19, JPN6023021143, 2001, pages 358 - 377, ISSN: 0005208442 *

Also Published As

Publication number Publication date
AU2019292580A1 (en) 2021-02-04
US20210261649A1 (en) 2021-08-26
EP3866924A4 (en) 2022-07-06
AU2019292580B2 (en) 2026-02-26
WO2020006486A1 (en) 2020-01-02
CA3103374A1 (en) 2020-01-02
JP2025186440A (ja) 2025-12-23
JP2024079815A (ja) 2024-06-11
EP3866924A1 (en) 2021-08-25
JP7749055B2 (ja) 2025-10-03

Similar Documents

Publication Publication Date Title
AU2019292580B2 (en) Compositions and methods for antibody delivery
EP3487528B1 (en) Extracellular vesicle comprising a fusion protein having fc binding capacity
JP2023002562A (ja) 抗ｔｌ１ａモノクローナル抗体の中和
CN114231512B (zh) 半胱氨酸蛋白酶
RU2568051C2 (ru) АНТИТЕЛА К ErbB3
TW202136314A (zh) 抗ｃｃｒ８抗體及其用途
JP2018510622A (ja) システインプロテアーゼ
JP2012507299A (ja) Ｌｉｇｈｔ標的分子およびその使用
TW200403254A (en) Antibodies
JP2022521428A (ja) 抗炎症剤に連結されたｅｃｍ親和性ペプチドを用いて炎症性状態および自己免疫状態を処置するための方法および組成物
US20250223376A1 (en) Compositions and methods for the treatment of her2 positive cancer
US20180362624A1 (en) Ig1 and the therapeutic use thereof
CN116724051A (zh) 用于通过靶向igsf8来治疗自身免疫性疾病和癌症的组合物和方法
US20230212610A1 (en) Nucleic acid expression using subcutaneous administration
EP4663656A2 (en) Masp-2 and masp-3 inhibitors, and related compositions and methods, for treatment of sickle cell disease
CN114591428B (zh) 抗Dsg1抗体及其应用
WO2025186779A1 (en) Oncolytic viruses expressing immunomodulators and use for treating advanced solid tumor
WO2025222147A1 (en) Expression of pd-l1 to improve gene therapy efficacy
JP2025538489A (ja) 抗ｃｄ８アルファ枯渇抗体
WO2026085357A2 (en) Compositions comprising antibodies having pigr-binding peptides and methods of use thereof
RU2810206C1 (ru) Il-18-связывающий белок (il-18bp) и антитела при воспалительных заболеваниях
WO2025242732A1 (en) Pan antibodies against sars-cov-2 spike protein and uses thereof for therapeutical purposes
WO2024220732A1 (en) Endoglycosidase s2 (endos2) mutants and uses thereof
WO2025235413A1 (en) Compositions targeting cancer antigens and methods of use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220622

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220622

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230824

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231130